Abstract
Synthesis and evaluation of a novel cancer cell’s receptor-targeted internally quaternized and surface neutral poly(amidoamine) (PAMAM) generation four dendrimer as well as PAMAM–paclitaxel conjugate are described. The advantages of developed nanocarriers include but are not limited to (1) internal cationic charges for the complexation with small interfering RNA or antisense oligonucleotides and their protection from the degradation in systemic circulation; (2) neutral-modified surface for low cytotoxicity of empty unloaded dendrimers; (3) efficient internalization by cancer cells; and (4) preferential accumulation in the tumor and the prevention of adverse side effects of chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Khandare, J. J., Chandna, P., Wang, Y., Pozharov, V. P., and Minko, T. (2006) Novel polymeric prodrug with multivalent components for cancer therapy. J Pharmacol Exp Ther 317, 929–937.
Kratz, F., Muller, I. A., Ryppa, C., and Warnecke, A. (2008) Prodrug strategies in anticancer chemotherapy. ChemMedChem 3, 20–53.
Minko, T. (2004) Drug targeting to the colon with lectins and neoglycoconjugates. Adv Drug Deliv Rev 56, 491–509.
Minko, T., Dharap, S. S., Pakunlu, R. I., and Wang, Y. (2004) Molecular targeting of drug delivery systems to cancer. Curr Drug Targets 5, 389–406.
Singh, Y., Palombo, M., and Sinko, P. J. (2008) Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem 15, 1802–1826.
Allen, T. M. and Cullis, P. R. (2004) Drug delivery systems: entering the mainstream. Science 303, 1818–1822.
Chandna, P., Saad, M., Wang, Y., Ber, E., Khandare, J., Vetcher, A. A., Soldatenkov, V. A., and Minko, T. (2007) Targeted proapoptotic anticancer drug delivery system. Mol Pharm 4, 668–678.
Betigeri, S., Pakunlu, R. I., Wang, Y., Khandare, J. J., and Minko, T. (2006) JNK1 as a molecular target to limit cellular mortality under hypoxia. Mol Pharm 3, 424–430.
Caplen, N. J. and Mousses, S. (2003) Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells. Ann NY Acad Sci 1002, 56–62.
Gutierrez-Puente, Y., Tari, A. M., Ford, R. J., Tamez-Guerra, R., Mercado-Hernandez, R., Santoyo-Stephano, M., and Lopez-Berestein, G. (2003) Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line. Leuk Lymphoma 44, 1979–1985.
Kang, H., DeLong, R., Fisher, M. H., and Juliano, R. L. (2005) Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res 22, 2099–2106.
Lukyanov, A. N., Elbayoumi, T. A., Chakilam, A. R., and Torchilin, V. P. (2004) Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release 100, 135–144.
Pakunlu, R. I., Cook, T. J., and Minko, T. (2003) Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm Res 20, 351–359.
Pakunlu, R. I., Wang, Y., Saad, M., Khandare, J. J., Starovoytov, V., and Minko, T. (2006) In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release 114, 153–162.
Pakunlu, R. I., Wang, Y., Tsao, W., Pozharov, V., Cook, T. J., and Minko, T. (2004) Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res 64, 6214–6224.
Torchilin, V. P. (2006) Multifunctional nanocarriers. Adv Drug Deliv Rev 58, 1532–1555.
Torchilin, V. P. (2006) Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 8, 343–375.
Wang, Y. and Minko, T. (2004) A novel cancer therapy: combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and an anticancer drug. Biochem Pharmacol 68, 2031–2042.
Wang, Y., Saad, M., Pakunlu, R. I., Khandare, J. J., Garbuzenko, O. B., Vetcher, A. A., Soldatenkov, V. A., Pozharov, V. P., and Minko, T. (2008) Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1{alpha} enhances the efficacy of chemotherapy in drug-resistant tumor. Clin Cancer Res 14, 3607–3616.
Wang, Y., Pakunlu, R. I., Tsao, W., Pozharov, V., and Minko, T. (2004) Bimodal effect of hypoxia in cancer: the role of hypoxia inducible factor in apoptosis. Mol Pharm 1, 156–165.
Patil, M. L., Zhang, M., Betigeri, S., Taratula, O., He, H., and Minko, T. (2008) Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug Chem 19, 1396–1403.
Dharap, S. S. and Minko, T. (2003) Targeted proapoptotic LHRH-BH3 peptide. Pharm Res 20, 889–896.
Jayant, S., Khandare, J. J., Wang, Y., Singh, A. P., Vorsa, N., and Minko, T. (2007) Targeted sialic acid-doxorubicin prodrugs for intracellular delivery and cancer treatment. Pharm Res 24, 2120–2130.
Saad, M., Garbuzenko, O. B., and Minko, T. (2008) Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomed 3, 761–776.
Dharap, S. S., Wang, Y., Chandna, P., Khandare, J. J., Qiu, B., Gunaseelan, S., Sinko, P. J., Stein, S., Farmanfarmaian, A., and Minko, T. (2005) Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci USA 102, 12962–12967.
Saad, M., Garbuzenko, O. B., Ber, E., Chandna, P., Khandare, J. J., Pozharov, V. P., and Minko, T. (2008) Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release 130, 107–114.
Minko, T., Kopeckova, P., Pozharov, V., Jensen, K. D., and Kopecek, J. (2000) The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors. Pharm Res 17, 505–514.
Garbuzenko, O. B., Saad, M., Betigeri, S., Zhang, M., Vetcher, A. A., Soldatenkov, V. A., Reimer, D. C., Pozharov, V. P., and Minko, T. (2008) Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm Res [Oct 22 Epub ahead of print].
Acknowledgments
This research was supported in part by NIH grants CA100098 and CA111766 from the National Cancer Institute.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Minko, T. et al. (2010). LHRH-Targeted Nanoparticles for Cancer Therapeutics. In: Grobmyer, S., Moudgil, B. (eds) Cancer Nanotechnology. Methods in Molecular Biology, vol 624. Humana Press. https://doi.org/10.1007/978-1-60761-609-2_19
Download citation
DOI: https://doi.org/10.1007/978-1-60761-609-2_19
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-608-5
Online ISBN: 978-1-60761-609-2
eBook Packages: Springer Protocols